LncRNA-p21 alters the antiandrogen enzalutamide-induced prostate cancer neuroendocrine differentiation via modulating the EZH2/STAT3 signaling

SOX2 promotes lineage plasticity and antiandrogen resistance in TP53 - and RB1 -deficient prostate cancer

(2017) Ping Mu et al.   SCIENCE

Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance

(2017) Sheng Yu Ku et al.   SCIENCE

Metformin reverses prostate cancer resistance to enzalutamide by targeting TGF-β1/STAT3 axis-regulated EMT

(2017) Qiuli Liu et al.   Cell Death & Disease

N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer

(2016) Etienne Dardenne et al.   CANCER CELL

Long Noncoding RNAs in Cancer Pathways

(2016) Adam M. Schmitt et al.   CANCER CELL

Targeting EZH2 in cancer

(2016) Kimberly H Kim et al.   NATURE MEDICINE

ROR-γ drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer

(2016) Junjian Wang et al.   NATURE MEDICINE

Neuroendocrine prostate cancer (NEPCa) increased the neighboring PCa chemoresistance via altering the PTHrP/p38/Hsp27/androgen receptor (AR)/p21 signals

(2016) Y Cui et al.   ONCOGENE

The Master Neural Transcription Factor BRN2 Is an Androgen Receptor–Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer

(2016) Jennifer L. Bishop et al.   Cancer Discovery

Combination AZD5363 with Enzalutamide Significantly Delays Enzalutamide-resistant Prostate Cancer in Preclinical Models

(2015) Paul Toren et al.   EUROPEAN UROLOGY

Radiographic Progression-Free Survival As a Response Biomarker in Metastatic Castration-Resistant Prostate Cancer: COU-AA-302 Results

(2015) Michael J. Morris et al.   JOURNAL OF CLINICAL ONCOLOGY

The potential of neurotensin secreted from neuroendocrine tumor cells to promote gelsolin-mediated invasiveness of prostate adenocarcinoma cells

(2015) Kohei Hashimoto et al.   LABORATORY INVESTIGATION

Broad H3K4me3 is associated with increased transcription elongation and enhancer activity at tumor-suppressor genes

(2015) Kaifu Chen et al.   NATURE GENETICS

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer

(2015) Christopher J. Sweeney et al.   NEW ENGLAND JOURNAL OF MEDICINE

Niclosamide Inhibits Androgen Receptor Variants Expression and Overcomes Enzalutamide Resistance in Castration-Resistant Prostate Cancer

(2014) C. Liu et al.   CLINICAL CANCER RESEARCH

Agonist and antagonist switch DNA motifs recognized by human androgen receptor in prostate cancer

(2014) Z. Chen et al.   EMBO JOURNAL

Androgen deprivation–induced NCoA2 promotes metastatic and castration-resistant prostate cancer

(2014) Jun Qin et al.   JOURNAL OF CLINICAL INVESTIGATION

LincRNA-p21 Activates p21 In cis to Promote Polycomb Target Gene Expression and to Enforce the G1/S Checkpoint

(2014) Nadya Dimitrova et al.   MOLECULAR CELL

A new look at prostate cancer treatment complications

(2014) Matthew R. Cooperberg   Nature Reviews Clinical Oncology

Small cell carcinoma of the prostate

(2014) Rosa Nadal et al.   Nature Reviews Urology

Enzalutamide in Metastatic Prostate Cancer before Chemotherapy

(2014) Tomasz M. Beer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Long noncoding RNAs and prostate carcinogenesis: the missing ‘linc’?

(2014) Anna L. Walsh et al.   TRENDS IN MOLECULAR MEDICINE

Cooperativity and equilibrium with FOXA1 define the androgen receptor transcriptional program

(2014) Hong-Jian Jin et al.   Nature Communications

Phosphorylation of EZH2 Activates STAT3 Signaling via STAT3 Methylation and Promotes Tumorigenicity of Glioblastoma Stem-like Cells

(2013) Eunhee Kim et al.   CANCER CELL

Loss of Androgen Receptor Expression Promotes a Stem-like Cell Phenotype in Prostate Cancer through STAT3 Signaling

(2013) A. Schroeder et al.   CANCER RESEARCH

Targeting the androgen receptor with siRNA promotes prostate cancer metastasis through enhanced macrophage recruitment via CCL2/CCR2-induced STAT3 activation

(2013) Kouji Izumi et al.   EMBO Molecular Medicine

Next-generation Sequencing of Advanced Prostate Cancer Treated with Androgen-deprivation Therapy

(2013) Prabhakar Rajan et al.   EUROPEAN UROLOGY

Differential Androgen Deprivation Therapies with Anti-androgens Casodex/Bicalutamide or MDV3100/EnzalutamideversusAnti-androgen Receptor ASC-J9® Lead to PromotionversusSuppression of Prostate Cancer Metastasis

(2013) Tzu-Hua Lin et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches

(2013) T Karantanos et al.   ONCOGENE

Inhibition of constitutively active Stat3 reverses enzalutamide resistance in LNCaP derivative prostate cancer cells

(2013) Chengfei Liu et al.   PROSTATE

Anti-androgen receptor ASC-J9 versus anti-androgens MDV3100 (Enzalutamide) or Casodex (Bicalutamide) leads to opposite effects on prostate cancer metastasis via differential modulation of macrophage infiltration and STAT3-CCL2 signaling

(2013) T-H Lin et al.   Cell Death & Disease

LincRNA-p21 Suppresses Target mRNA Translation

(2012) Je-Hyun Yoon et al.   MOLECULAR CELL

EZH2 Oncogenic Activity in Castration-Resistant Prostate Cancer Cells Is Polycomb-Independent

(2012) K. Xu et al.   SCIENCE

BMP4 Promotes Prostate Tumor Growth in Bone through Osteogenesis

(2011) Y.-C. Lee et al.   CANCER RESEARCH

Modeling a Lethal Prostate Cancer Variant with Small-Cell Carcinoma Features

(2011) V. Tzelepi et al.   CLINICAL CANCER RESEARCH

The Polycomb complex PRC2 and its mark in life

(2011) Raphaël Margueron et al.   NATURE

Recurrent chimeric RNAs enriched in human prostate cancer identified by deep sequencing

(2011) K. Kannan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

PC3 is a cell line characteristic of prostatic small cell carcinoma

(2011) Sheng Tai et al.   PROSTATE

Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of New Drug Targets

(2011) H. Beltran et al.   Cancer Discovery

A Large Intergenic Noncoding RNA Induced by p53 Mediates Global Gene Repression in the p53 Response

(2010) Maite Huarte et al.   CELL

Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis

(2010) Rajnish A. Gupta et al.   NATURE

Differential androgen receptor signals in different cells explain why androgen-deprivation therapy of prostate cancer fails

(2010) Y Niu et al.   ONCOGENE

Sp1 Phosphorylation and Its Regulation of Gene Transcription

(2009) N. Y. Tan et al.   MOLECULAR AND CELLULAR BIOLOGY

Stat3 Promotes Metastatic Progression of Prostate Cancer

(2008) Junaid Abdulghani et al.   AMERICAN JOURNAL OF PATHOLOGY

Androgen receptor and growth factor signaling cross-talk in prostate cancer cells

(2008) M.-L. Zhu et al.   ENDOCRINE-RELATED CANCER

Androgen receptor is a tumor suppressor and proliferator in prostate cancer

(2008) Y. Niu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA